Ampio Announces Investor Call on its Aytu BioScience Common Stock Distribution on Thursday, November 19, 4:15 p.m. EST

ENGLEWOOD, Colo., November 18, 2015 — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced webcast and dial-in details for a scheduled investor web presentation that will occur on Thursday, November 19, 4:15 p.m. EST. The presentation will discuss Ampio’s distribution to its existing stockholders of shares of common stock of Aytu BioScience, Inc. (OTCQB: AYTU) as well as Aytu’s current business plans. Participants are invited to join the live webcast with slide presentation and accompanying audio by using the link below:

Investor webcast information:
If this link doesn’t take you directly to the meeting click on “Accept Terms and Use Meeting Web Access” at the bottom of the page which will redirect you to the webcast.

On the “Enter Meeting” page that appears, supply this information:
Your Name: Enter Your Name
Meeting ID: w413596
Entry Code: A413596
After entering this information click on “Join Meeting”.

This link can also be found on the Ampio web page at:

If participants wish to participate by phone for audio only, they may use the following dial-in information.

Investor call (for audio only) information:
U.S./Canada toll-free number: 1-888-208-1815
International toll number: 719-457-2623
Participant Passcode: 413596

To ask questions after the formal presentation access will be provided through an operator for Q&A, and participants will be instructed on how to submit questions at the time of the call.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.  We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Investor Contact
Gregory A. Gould
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6513

About Aytu BioScience, Inc.
Aytu BioScience, Inc. is a commercial-stage specialty healthcare company focused on urological and related conditions.  The Company’s products includes FDA-approved ProstaScint®(capromab pendetide), a radio-labeled monoclonal antibody that targets Prostate Specific Membrane Antigen (PSMA), a protein highly expressed by prostate cancer; as well as Primsol®(trimethoprim oral solution), the only FDA-approved oral solution of trimethoprim, the standard therapy for urinary tract infections.  Aytu’s strategy is to continue building its portfolio of revenue-generating urology products and late-stage development assets, leveraging its commercial team and expertise to further build those brands within well-established markets.

Investors & Media Contacts
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.:; (212) 375-2664
Janine McCargo:; (646) 604-5150

Forward Looking Statements
Ampio’s statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by use of words such as “plan,” “continue”, “present,” “could,” “may,” “will be,” and similar expressions.  These forward-looking statements include statements regarding Ampio’s plans with respect to the distribution of Aytu shares, Aytu’s business plans, AmpionTM and OptinaTM and their affects, which are subject to the risks associated with clinical trials, regulatory approvals, and changes in business conditions and similar events.  These forward-looking statements also include statements regarding Aytu’s strategic plans and their ability to acquire potential products.  These risks include the uncertainty of the regulatory response to the sufficiency of trial data and trial design, that regulatory approval may not be obtained or delayed, the risks and uncertainties detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and, the risks of timing or the ability to effect the Aytu spin-off.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.